Peter Kohn speaks at the ABA Section of Antitrust Law’s 64th Annual Spring Meeting
Peter Kohn was an invited speaker at the Health Care & Pharmaceuticals and State Enforcement Committee’s program, “Exclusionary or Not? Product Hopping and REMS,” on April 6 at the ABA Section of Antitrust Law’s 2016 Spring Meeting in Washington, D.C. He was joined by Seth Silber of Wilson Sonsini Goodrich & Rosati, P.C., George Gordon of Dechert LLP, Dr. Fiona M. Scott Morton of Yale’s School of Management, and Heather Johnson of the Federal Trade Commission’s Healthcare Division. Mr. Kohn answered questions from the perspective of a generic drug company concerning why product hopping — changing the brand drug product to prevent an imminent generic version from being substitutable at the pharmacy counter — represents an exercise of a brand drug company’s market power, why withholding samples of a restricted-distribution drug may be cognizably anticompetitive, and how existing antitrust precedent construing Section 2 of the Sherman Act is sufficient to condemn such conduct. Mr. Kohn was last invited to speak at the Section of Antitrust Law’s Spring Meeting in 2011, on the topic of resale price maintenance.
About Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP focuses on complex civil litigation, including securities, antitrust, wage and hour, and consumer class actions as well as shareholder derivative and merger and transactional litigation. The firm is headquartered in New York, and maintains offices in California, Delaware and Pennsylvania.
Since its founding in 1995, Faruqi & Faruqi, LLP has served as lead or co-lead counsel in numerous high-profile cases which ultimately provided significant recoveries to investors, consumers and employees.
To schedule a free consultation with our attorneys and to learn more about your legal rights, call our offices today at (877) 247-4292.
About Peter Kohn
Peter Kohn is chair of Faruqi & Faruqi LLP’s antitrust department, having joined the firm as a partner in 2010. He has practiced antitrust law since 2000. The firm currently is representing proposed classes of direct purchasers in two cases alleging that product hopping by a brand drug company suppressed generic competition, Suboxone and Namenda. Previously the firm represented purchasers in similar cases, Doryx and Tricor.